首页> 外文OA文献 >PCN80 THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN: RESULTS FROM A COST-EFFECTIVENESS ANALYSIS

【2h】

PCN80 THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN: RESULTS FROM A COST-EFFECTIVENESS ANALYSIS

机译：PCN80在瑞典患有晚期或复发性非小细胞肺癌（NSCLC）的患者中，贝伐单抗+西西他汀和吉西他滨（BCG）相对于西妥昔单抗+长春瑞滨+西西拉汀（CVC）的益处：结果是C结果的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Nuijten MJ; Holmberg C; Walzer S;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. 9164 An indirect comparison of the efficacy of bevacizumab plus cisplatin and gemcitabine (BCG) or bevacizumab plus carboplatin and paclitaxel (BCP) versus pemetrexed plus cisplatin (PC) and cetuximab plus vinorelbine and cisplatin (CVC) in patients (pts) with advanced or recurrent non-small cell cancer (NSCLC) [J] . S.Walzer, J.de Castro Carpeno, A.V.Vergnenegre, European Journal of Cancer Supplements . 2009,第2期

机译：9164贝伐单抗加顺铂和吉西他滨（BCG）或贝伐单抗加卡铂和紫杉醇（BCP）与培美曲塞加顺铂（PC）和西妥昔单抗加长春瑞滨和顺铂（CVC）的间接疗效比较非小细胞癌（NSCLC）
2. 6509 ORAL Management of hypertension (HTN) in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) receiving first-line cisplatin and gemcitabine with bevacizumab or placebo – results from randomised phase III trial BO17704 [J] . J.Bennouna, J.vonPawel, P.Zatloukal, European Journal of Cancer Supplements . 2007,第4期

机译：接受一线顺铂和吉西他滨联合贝伐单抗或安慰剂治疗的晚期或复发性非鳞状非小细胞肺癌（NSCLC）患者的6509 ORAL口服高血压治疗（HTN）–来自III期随机试验BO17704的结果
3. 6503 ORAL Efficacy and safety results from BO17704, a randomised, placebo-controlled phase III study of bevacizumab in combination with cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC) [J] . C.Manegold, J.vonPawel, P.Zatloukal, European Journal of Cancer Supplements . 2007,第4期

机译：6503口服功效的有效性和安全性来自BO17704，这是一项贝伐单抗联合顺铂和吉西他滨对晚期或复发性非鳞状非小细胞肺癌（NSCLC）患者进行的随机，安慰剂对照的III期临床研究
4. Enumeration and ALK Investigation of Circulating Tumor Cells in Non-Small Cell Lung Cancer (NSCLC) Patients Using an Effective In Vivo Technology, the GILUPI CellCollector? [C] . Klaus Luecke, Lukasz Gasiorowski, Stefanie Herold, International Molecular Medicine Tri-Conference. . 2015

机译：使用有效的体内技术（Gilupi Cellcollector
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONICAP randomized phase II study. Italian Lung Cancer Task Force (FONICAP). [O] . E. Baldini, C. Tibaldi, A. Ardizzoni, 1998

机译：晚期非小细胞肺癌（NSCLC）患者的顺铂-长春地霉素-丝裂霉素（MVP）与顺铂-异环磷酰胺-长春瑞滨（PIN）与卡铂-长春瑞滨（CaN）：一项FONICAP随机II期研究。意大利肺癌工作组（FONICAP）。
7. PCN89 A COST EFFECTIVENESS ANALYSIS DEMONSTRATES THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN [O] . de Castro Carpeño J, Castro Gómez A, Walzer S 2009

机译：PCN89成本效益分析证明了患有晚期或复发性非小细胞肺癌的患者接受贝伐单抗加西沙丁胺和吉西他滨（BCG）与西妥昔单抗加长春新碱和西斯拉丁（CVC）的益处。

PCN80 THE BENEFITS OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN: RESULTS FROM A COST-EFFECTIVENESS ANALYSIS

著录项

引文网络

相似文献

相关主题

期刊订阅